File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Comparison of ondansetron with metoclopramide in the control of emesis induced by moderately emetogenic chemotherapy used for lymphoma and leukaemia patients

TitleComparison of ondansetron with metoclopramide in the control of emesis induced by moderately emetogenic chemotherapy used for lymphoma and leukaemia patients
Authors
Issue Date1994
PublisherAdis International Ltd. The Journal's web site is located at http://druginvestigation.adisonline.com
Citation
Drug Investigation, 1994, v. 8 n. 2, p. 104-109 How to Cite?
AbstractOndansetron was compared with conventional-dose metoclopramide in a randomised trial for emesis control in 56 patients with lymphoma and leukaemia receiving commonly used chemotherapeutic regimens that are moderately emetogenic. Emetogenic chemotherapeutic agents were administered on day 1 to lymphoma patients and on days 1 to 5 to leukaemia patients. Ondansetron was superior to metoclopramide in the complete control of acute emesis (75 vs 43%, p = 0.03). Control of delayed emesis in lymphoma patients was marginally better with ondansetron on days 2 (89 vs 64%, p = 0.140) and 3 (94 vs 68%, p = 0.054). Continuous control of emesis for leukaemia patients on daily chemotherapy was better with ondansetron on days 3 (80 vs 17%, p = 0.035) and 4 (90 vs 33%, p = 0.036). Furthermore, significantly more patients on ondansetron enjoyed normal food intake on day 1 (71 vs 14%, p = 0.000). Both antiemetic regimens were well tolerated. No extrapyramidal reactions were observed.
Persistent Identifierhttp://hdl.handle.net/10722/162035
ISSN

 

DC FieldValueLanguage
dc.contributor.authorChiu, EKWen_US
dc.contributor.authorLiang, Ren_US
dc.contributor.authorLie, Aen_US
dc.contributor.authorTodd, Den_US
dc.contributor.authorChan, TKen_US
dc.date.accessioned2012-09-05T05:16:48Z-
dc.date.available2012-09-05T05:16:48Z-
dc.date.issued1994en_US
dc.identifier.citationDrug Investigation, 1994, v. 8 n. 2, p. 104-109en_US
dc.identifier.issn0114-2402en_US
dc.identifier.urihttp://hdl.handle.net/10722/162035-
dc.description.abstractOndansetron was compared with conventional-dose metoclopramide in a randomised trial for emesis control in 56 patients with lymphoma and leukaemia receiving commonly used chemotherapeutic regimens that are moderately emetogenic. Emetogenic chemotherapeutic agents were administered on day 1 to lymphoma patients and on days 1 to 5 to leukaemia patients. Ondansetron was superior to metoclopramide in the complete control of acute emesis (75 vs 43%, p = 0.03). Control of delayed emesis in lymphoma patients was marginally better with ondansetron on days 2 (89 vs 64%, p = 0.140) and 3 (94 vs 68%, p = 0.054). Continuous control of emesis for leukaemia patients on daily chemotherapy was better with ondansetron on days 3 (80 vs 17%, p = 0.035) and 4 (90 vs 33%, p = 0.036). Furthermore, significantly more patients on ondansetron enjoyed normal food intake on day 1 (71 vs 14%, p = 0.000). Both antiemetic regimens were well tolerated. No extrapyramidal reactions were observed.en_US
dc.languageengen_US
dc.publisherAdis International Ltd. The Journal's web site is located at http://druginvestigation.adisonline.com-
dc.relation.ispartofDrug Investigationen_US
dc.titleComparison of ondansetron with metoclopramide in the control of emesis induced by moderately emetogenic chemotherapy used for lymphoma and leukaemia patientsen_US
dc.typeArticleen_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1007/BF03257433-
dc.identifier.scopuseid_2-s2.0-0028085997en_US
dc.identifier.hkuros4675-
dc.identifier.volume8en_US
dc.identifier.issue2en_US
dc.identifier.spage104en_US
dc.identifier.epage109en_US
dc.publisher.placeNew Zealand-
dc.identifier.scopusauthoridChiu, EKW=24827833600en_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US
dc.identifier.scopusauthoridLie, A=24284842400en_US
dc.identifier.scopusauthoridTodd, D=7201388182en_US
dc.identifier.scopusauthoridChan, TK=7402687762en_US
dc.customcontrol.immutablejt 130726-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats